ReviewMolecular psychiatry2012
Little things on which happiness depends: microRNAs as novel therapeutic targets for the treatment of anxiety and depression.
Review in Molecular psychiatry, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed.
- MicroRNAs expression changes associated with trauma-focused psychotherapy efficacy in treatment-resistant depression: An exploratory study.Neuroscience applied · 2026Article
- MicroRNAs: A Novel Approach for Monitoring Treatment Response in Major Depressive Disorder?Non-coding RNA · 2025Review
- Deciphering the role of miRNA-134 in the pathophysiology of depression: A comprehensive review.Heliyon · 2024Review
- Exploring mood disorders and treatment options using human stem cells.Genetics and molecular biology · 2024Article
- Baseline levels of miR-223-3p correlate with the effectiveness of electroconvulsive therapy in patients with major depression.Translational psychiatry · 2023Article
- miR-483-5p offsets functional and behavioural effects of stress in male mice through synapse-targeted repression of Pgap2 in the basolateral amygdala.Nature communications · 2023Article
- Article
- Cannabidiol Modulates Alterations in PFC microRNAs in a Rat Model of Depression.International journal of molecular sciences · 2023Article
- Article
- The miRNome of Depression.International journal of molecular sciences · 2021Review
- In search of sex-related mediators of affective illness.Biology of sex differences · 2021Review
- Article
- Molecular Biomarkers of Electroconvulsive Therapy Effects and Clinical Response: Understanding the Present to Shape the Future.Brain sciences · 2021Review
- Maternal antioxidant treatment prevents the adverse effects of prenatal stress on the offspring's brain and behavior.Neurobiology of stress · 2020Article
- Non-coding RNAs in neuropathic pain.Neuronal signaling · 2020Review
- Circulating microRNA 134 sheds light on the diagnosis of major depressive disorder.Translational psychiatry · 2020Article
- MicroRNA134 of Ventral Hippocampus Is Involved in Cocaine Extinction-Induced Anxiety-like and Depression-like Behaviors in Mice.Molecular therapy. Nucleic acids · 2020Article
- MicroRNA-34a Regulates the Depression-like Behavior in Mice by Modulating the Expression of Target Genes in the Dorsal Raphè.Molecular neurobiology · 2020Article
- MiR-124 suppression in the prefrontal cortex reduces depression-like behavior in mice.Bioscience reports · 2019Article
- miR-132/212 is induced by stress and its dysregulation triggers anxiety-related behavior.Neuropharmacology · 2019Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Anxiety and depression are devastating mental illnesses that are a significant public health concern. Selective serotonin-reuptake inhibitors are the first-line treatment strategy for these disorders, which despite being a significant advantage over older treatments, are hampered by a limited efficacy in a significant subset of patients, delayed onset of action and side effects that affect compliance. Thus, there is much impetus to develop novel therapeutic strategies. However, this goal can only be rationally realised with a better understanding of the molecular pathophysiology of these disorders. MicroRNAs (miRNAs) are a newly discovered class of gene-expression regulators that may represent a novel class of therapeutic targets to treat a variety of disorders including psychiatric diseases. miRNAs are heavily involved in regulating many physiological processes including those fundamental to the functioning of the central nervous system. Evidence collected to date has already demonstrated that miRNA-expression levels are altered in patients suffering from depression and anxiety and in pre-clinical models of psychological stress. Furthermore, increasing evidence suggests that psychoactive agents including antidepressants and mood stabilisers utilise miRNAs as downstream effectors. Altering miRNA levels has been shown to alter behaviour in a therapeutically desirable manner in pre-clinical models. This review aims to outline the evidence collected to date demonstrating miRNAs role in anxiety and depression, the potential advantages of targeting these small RNA molecules as well as some of the hurdles that will have to be overcome to fully exploit their therapeutic potential.
Indexed as
Identifiers
22182940What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.